Globus Medical Inc. reported fourth‑quarter 2025 net sales of $826.4 million, a 25.7% increase from the $656.5 million reported a year earlier. GAAP net income rose to $140.6 million, giving a diluted EPS of $1.03, while non‑GAAP diluted EPS reached $1.28, a 52.1% year‑over‑year gain. Full‑year 2025 sales totaled $2.9389 billion, up 16.7% from $2.4569 billion a year earlier. The company raised its 2026 revenue guidance to $3.18‑$3.22 billion, unchanged from the preliminary guidance issued on January 7, 2026, and lifted its adjusted‑EPS guidance to $4.40‑$4.50 from $4.30‑$4.40.
The revenue growth was driven by a 19% year‑over‑year increase in the enabling‑technologies segment and continued momentum in the core spine franchise. The Nevro acquisition, closed in Q2 2025, contributed significantly to the top line and was EPS‑accretive within nine months. Base‑business net sales for the full year were $2.6453 billion, while enabling‑technologies sales were $141 million. The company’s integration of NuVasive and Nevro has expanded its product portfolio and international footprint, supporting the robust sales performance.
The GAAP EPS beat analyst expectations by $0.22, driven by strong demand in the spine and enabling‑technology markets and disciplined cost management. Adjusted gross margin expanded to 69.2% from 67.1% a year earlier, and adjusted EBITDA margin rose to 33.9%, reflecting operational leverage and a favorable product mix. The company’s non‑GAAP EPS of $1.28 surpassed the consensus estimate of $1.06, a beat of $0.22, underscoring the effectiveness of its integration strategy and pricing power.
Management’s guidance signals confidence in sustained growth. The raised adjusted‑EPS range of $4.40‑$4.50 reflects expectations of continued margin expansion and a strong demand pipeline, while the unchanged revenue guidance indicates a stable top‑line outlook amid a competitive market. The company expects to maintain its operational leverage and continue to benefit from the expanded product portfolio.
"Momentum built throughout 2025 accelerated in the fourth quarter, capping off a strong finish to the year with double‑digit sales and earnings growth," said President and CEO Keith Pfeil. "Our revenue grew 10% over the prior‑year quarter, driven by strong demand in our core spine business and a rebound in enabling technologies. The integration of NuVasive and Nevro has accelerated our growth trajectory and positioned us for continued success."
"Our revenue growth was driven by our domestic spine business, growing 10% over the fourth quarter of 2024, and our record‑setting results were punctuated by an exceptional quarter in enabling technologies, growing 19% over the fourth quarter of 2024," said Chief Financial Officer Kyle Kline. "The revised fully diluted non‑GAAP earnings per share guidance reflects our confidence in sustained margin expansion as we seek to drive above‑market profitable growth."
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.